Dergiler / European Journal of Rheumatology / 2017 / Cilt: 4 - Sayı: 2

Catastrophic antiphospholipid syndrome treated with rituximab: A case report

Sayfa
145–147
Yayın Tarihi
2022-10-18
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Rituximab may be an effective treatment option for patients with CAPS.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Catastrophic antiphospholipid syndrome (CAPS) is a rare and fatal condition that is characterized by diffuse venous and/or arterial thromboembolism within a short period of time and histopathological confirmation of small-vessel occlusion in at least one organ or tissue in the presence of positive antiphospholipid antibodies.
📊
Temel Bulgular & Veri:Here we report the case of a 19-year-old woman with CAPS.
💡
Sonuç & Katkı:Rituximab may be an effective treatment option for patients with CAPS.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Catastrophic antiphospholipid syndrome (CAPS) is a rare and fatal condition that is characterized by diffuse venous and/or arterial thromboembolism within a short period of time and histopathological confirmation of small-vessel occlusion in at least one organ or tissue in the presence of positive antiphospholipid antibodies. Here we report the case of a 19-year-old woman with CAPS. During the first week of her hospitalization, she was diagnosed with CAPS on the basis of skin necrosis, pulmonary artery thrombosis, cerebral venous sinus thrombosis, and positive lupus anticoagulant. She was treated with corticosteroids, intravenous immunoglobulins, plasmapheresis, and anticoagulants. Forty days after the onset of CAPS, cutaneous lesions were recurred during skin surgery. She required a high dose of corticosteroids, intravenous immunoglobulins, and rituximab. No further thrombotic events occurred. Rituximab may be an effective treatment option for patients with CAPS.

🔖

Bu Makaleye Atıf Yap

KARAHAN, N., ŞAHİN, M., DOĞRU, A., UGAN, Y., TUNÇ, Ş. E. (2022). Catastrophic antiphospholipid syndrome treated with rituximab: A case report. European Journal of Rheumatology, Cilt: 4 - Sayı: 2, 145–147. https://ajindex.com/articles/511705

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (3)

  1. Abdel-Wahab N, Lopez-Olivo MA, Pinto-Patarroyo GP, Suarez-Almozor ME. Systematic review of case reports of antiphospholipid syndrome following infection. Lupus 2016; 25: 1520-31. [CrossRef] Berman H, Rodriquez-Pinto I, Cervera R, Morel N, Costedoat-Chalumeau N, Erkan D, et al. Rit- uximab use in the catastrophic antiphospholip- id syndrome: Descriptive analysis of the CAPS registry receiving rituximab. Autoimmun Rev 2013; 12: 1085-90. [CrossRef ] Espinosa G, Cervera R, Asherson RA. Catastroph- ic antiphospholipid syndrome and sepsis. A common link? J Rheumatol 2007; 34: 923-6.
  2. Ortel TL, Erkan D, Kitchens CS. How I treat cat- astrophic thrombotic syndromes. Blood 2015; 126: 1285-93. [CrossRef ] Cervera R, Rodriguez-Pinto I, Colafrancesco S, Conti F, Valesini G, Rosario C, et al. 14th Interna- tional Congress on Antiphospholipid Antibod- ies Task Force Report on Catastrophic Antiphos- pholipid Syndrome. Autoimmun Rev 2014; 13: 699-707. [CrossRef ] Sukara G, Baresic M, Sentic M, Brcic L, Anic B. Catastrophic antiphospholipid syndrome associ- ated with systemic lupus erythematosus treated with rituximab: case report and a review of the literature. Acta Reumatol Port 2015; 40: 169-75.
  3. Rodriquez-Pinto I, Cervera R, Espinosa G. Rit- uximab and its therapeutic potential in cata- strophic antiphospholipid syndrome. Ther Adv Musculoskelet Dis 2015; 7: 26-30.[CrossRef ]